Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations : ASCO Living Guideline, Version 2022.3
Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis; as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating provider and do not account for individual variation among patients. See appendix for disclaimers and other important information (Appendix 1 and Appendix 2). Updates are published regularly and can be found at https://ascopubs.org/nsclc-da-living-guideline.
| Errataetall: |
UpdateOf: J Clin Oncol. 2022 Oct 1;40(28):3310-3322. - PMID 35816666 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 41(2023), 11 vom: 10. Apr., Seite e31-e41 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jaiyesimi, Ishmael A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 07.04.2023 Date Revised 28.05.2023 published: Print-Electronic UpdateOf: J Clin Oncol. 2022 Oct 1;40(28):3310-3322. - PMID 35816666 Citation Status MEDLINE |
|---|
| doi: |
10.1200/JCO.22.02782 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353087807 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353087807 | ||
| 003 | DE-627 | ||
| 005 | 20231226055212.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.22.02782 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1176.xml |
| 035 | |a (DE-627)NLM353087807 | ||
| 035 | |a (NLM)36802359 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jaiyesimi, Ishmael A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations |b ASCO Living Guideline, Version 2022.3 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.04.2023 | ||
| 500 | |a Date Revised 28.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a UpdateOf: J Clin Oncol. 2022 Oct 1;40(28):3310-3322. - PMID 35816666 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis; as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating provider and do not account for individual variation among patients. See appendix for disclaimers and other important information (Appendix 1 and Appendix 2). Updates are published regularly and can be found at https://ascopubs.org/nsclc-da-living-guideline | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Owen, Dwight H |e verfasserin |4 aut | |
| 700 | 1 | |a Ismaila, Nofisat |e verfasserin |4 aut | |
| 700 | 1 | |a Blanchard, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Celano, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Florez, Narjust |e verfasserin |4 aut | |
| 700 | 1 | |a Jain, Dharamvir |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Navneet |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology : official journal of the American Society of Clinical Oncology |d 1986 |g 41(2023), 11 vom: 10. Apr., Seite e31-e41 |w (DE-627)NLM012608777 |x 1527-7755 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2023 |g number:11 |g day:10 |g month:04 |g pages:e31-e41 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1200/JCO.22.02782 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2023 |e 11 |b 10 |c 04 |h e31-e41 | ||